Showing posts with label cognition. Show all posts
Showing posts with label cognition. Show all posts

Sunday, April 29, 2018

Seven brain benefits of turmeric

Caregivers, and healthcare professionals,here is some great information

Here is a great dementia resource for caregivers and healthcare professionals,

Your residents will love the Amazon Kindle Fire

Here is information on being the best caregiver you can be

Here is a way for nurses administrators, social workers and other health care  professionals to get an easyceu or two

Follow alzheimersideas on twitter

The Dementia Caregiver's Little Book of Hope [Kindle Edition]



Salk Institute's J147 is a derivative of turmeric, a spice used in curry. Learn how it quickly reverses memory deficits and has a host of unexpected anti-aging effects in the lab. 




Salk Institute researchers have found that J147, which is an experimental drug candidate aimed at combating Alzheimer's disease, has a host of unexpected anti-aging effects in animals.

J147, Alzheimer's and Old Age

The Salk team expanded upon their previous development of the drug candidate they labeled J147. It is a derivative of the common spice, turmeric, and takes a different tack by targeting Alzheimer's major risk factor -- old age. In the new work, the team showed that the drug candidate worked well in a mouse model of aging not typically used in Alzheimer's research. When these mice were treated with J147, they had better memory and cognition, healthier blood vessels in the brain and other improved physiological features, as detailed in the journal Aging.

Fighting Alzheimer's By Fighting Aging

"Initially, the impetus was to test this drug in a novel animal model that was more similar to 99 percent of Alzheimer's cases," says Antonio Currais, the lead author and a member of Professor David Schubert's Cellular Neurobiology Laboratory at Salk. "We did not predict we'd see this sort of anti-aging effect, but J147 made old mice look like they were young, based upon a number of physiological parameters."

Alzheimer's disease is a progressive brain disorder, recently ranked as the third leading cause of death in the United States and affecting more than five million Americans. It is also the most common cause of dementia in older adults, according to the National Institutes of Health.

"While most drugs developed in the past 20 years target the amyloid plaque deposits in the brain (which are a hallmark of the disease), none have proven effective in the clinic," says Schubert, senior author of the study.

Expanding the Fight to More Common Dementias

Several years ago, Schubert and his colleagues began to approach the treatment of the disease from a new angle. Rather than target amyloid, the lab decided to zero in on the major risk factor for the disease--old age. Using cell-based screens against old age-associated brain toxicities, they synthesized J147.

Previously, the team found that J147 could prevent and even reverse memory loss and Alzheimer's pathology in mice that have a version of the inherited form of Alzheimer's, the most commonly used mouse model. However, this form of the disease comprises only about 1 percent of Alzheimer's cases. For everyone else, old age is the primary risk factor, says Schubert. The team wanted to explore the effects of the drug candidate on a breed of mice that age rapidly and experience a version of dementia that more closely resembles the age-related human disorder.

Young Mice, Old Mice and J147-fed Mice

In this latest work, the researchers used a comprehensive set of assays to measure the expression of all genes in the brain, as well as over 500 small molecules involved with metabolism in the brains and blood of three groups of the rapidly aging mice. The three groups of rapidly aging mice included one set that was young, one set that was old and one set that was old but fed J147 as they aged.

7 Benefits

The old mice fed J147 saw the following benefits:
  1. They performed better on memory and other tests for cognition
  2. They displayed more robust motor movements.
  3. They had fewer pathological signs of Alzheimer's in their brains.
  4. J147 prevented the leakage of blood from the microvessels in the brains of old mice. "Damaged blood vessels are a common feature of aging in general, and in Alzheimer's, it is frequently much worse," says Currais.

    Importantly, because of the large amount of data collected on the three groups of mice, it was possible to demonstrate that many aspects of gene expression and metabolism in the old mice fed J147 were very similar to those of the young animals. These included:
  5. markers for increased energy metabolism,
  6. reduced brain inflammation and
  7. reduced levels of oxidized fatty acids in the brain.

Human Clinical Trials

Currais and Schubert note that while these studies represent a new and exciting approach to Alzheimer's drug discovery and animal testing in the context of aging, the only way to demonstrate the clinical relevance of the work is to move J147 into human clinical trials for Alzheimer's disease.

"If proven safe and effective for Alzheimer's, the apparent anti-aging effect of J147 would be a welcome benefit," adds Schubert. The team aims to begin human trials next year.


Tuesday, August 8, 2017

Does fish oil improve cognition

Caregivers, and healthcare professionals,here is some great information

Here is a great dementia resource for caregivers and healthcare professionals,

Your residents will love the Amazon Kindle Fire

Here is information on being the best caregiver you can be

Here is a way for nurses administrators, social workers and other health care  professionals to get an easyceu or two

Follow alzheimersideas on twitter

The Dementia Caregiver's Little Book of Hope [Kindle Edition]

DNI (The Alzheimer's Disease Neuroimaging Initiative) is one of the world's largest Alzheimer's research projects. ADNI researchers examined how fish oil supplements relates to improvements in cognitive decline and brain atrophy. What they found is worth knowing. 




PROVIDENCE, R.I. –Rhode Island Hospital researchers have completed a study that found regular use of fish oil supplements (FOS) was associated with a significant reduction in cognitive decline and brain atrophy in older adults. The study examined the relationship between FOS use during the Alzheimer's Disease Neuroimaging Initiative (ADNI) and indicators of cognitive decline. The findings are published in the journal, Alzheimer's & Dementia.

"At least one person is diagnosed every minute with Alzheimer's disease (AD) and despite best efforts, we have not yet found a cure for this pervasive and debilitating disease," said principal investigator Lori Daiello, PharmD, of the Alzheimer's Disease and Memory Disorders Center at Rhode Island Hospital. "The field is currently engaged in numerous studies to find better treatments for people suffering with AD; however, researching ways to prevent AD or slow cognitive decline in normal aging is of utmost importance."

In this retrospective study, older adults involved in the ADNI study were assessed with neuropsychological tests and brain magnetic resonance imaging (MRI) every six months. The group included 229 older adults who were cognitively normal; 397 who were diagnosed with mild cognitive impairment; and 193 with AD.

The study found that fish oil supplement use during the study was associated with significantly lower rates of cognitive decline as measured by the Alzheimer's Disease Assessment Scale (ADAS-cog), and the Mini Mental State Exam (MMSE), but this benefit was observed only for the group of participants without dementia at the time of enrollment.

"Additionally, serial brain imaging conducted during this study showed that the participants with normal cognition who reported taking fish oil supplements demonstrated less brain shrinkage in key neurological areas, compared to those who did not use the supplements," Daiello said. "Also, the positive findings on cognitive testing and brain MRI were only observed in persons who did not carry the best-studied genetic risk factor for AD, APOE-4. More research is needed, but these findings are promising and highlight the need for future studies to expand the current knowledge of the effects of FOS use on cognitive aging and AD."



This research was funded by from the Agency for HealthCare Research and Quality (AHRQ) (K08 HS017735); National Institute on Alcohol Abuse and Alcoholism (NIAAA) (R00AA020235, P01AA019072, and R01NS080655); National Cancer Institute (R03 CA153942, R01 CA155381); National Institute of Nursing Research (R01 NR011295); National Heart, Lung and Blood Institute (R01HL109116, R01 CA159954, 5T32HL076134, R01 HL064342); National Center for Complementary and Alternative Medicine (R01AT006948); National Institute on Drug Abuse (R01 DA021729, R34 DA031057); National Institute of Diabetes and Digestive Kidney Disorders (R18 DK075371); National Institutes of Health (R01 HL089311, U01 CA1503878; R34 DA031057-02, P01 AA019072, R01 NS036524, R01 HL084178, R01 DA020725, R56 DK075119, and R01 MH074368); and support from Pfizer; Janssen; Baxter, Eli Lilly and Avid pharmaceutical companies. Daiello's principal affiliation is Rhode Island Hospital, and she also holds academic appointments in the department of neurology (research) at The Warren Alpert Medical School of Brown University and Health Services, Policy & Practice in the Brown University School of Public Health. Other current and former Lifespan researchers involved in the study are Brian Ott, M.D (Rhode Island Hospital; Shira Dunsiger, Ph.D, of The Miriam Hospital, Assawin Gongvatana, Ph.D (University of California San Diego), and Ronald A. Cohen, Ph.D., (University of Florida).

About Rhode Island Hospital

Founded in 1863, Rhode Island Hospital in Providence, R.I., is a private, not-for-profit hospital and is the principal teaching hospital of The Warren Alpert Medical School of Brown University. A major trauma center for southeastern New England, the hospital is dedicated to being on the cutting edge of medicine and research. Last year, Rhode Island Hospital received more than $55 million in external research funding. It is also home to Hasbro Children's Hospital, the state's only facility dedicated to pediatric care. For more information on Rhode Island Hospital, visit http://www.rhodeislandhospital.org, follow us on Twitter @RIHospital or like us on Facebook http://www.facebook.com/rhodeislandhospitalpage.



Monday, July 31, 2017

Could Snoring be linked to Alzheimers

Caregivers, and healthcare professionals,here is some great information

Here is a great dementia resource for caregivers and healthcare professionals,

Your residents will love the Amazon Kindle Fire

Here is information on being the best caregiver you can be

Here is a way for nurses administrators, social workers and other health care  professionals to get an easyceu or two

Follow alzheimersideas on twitter

The Dementia Caregiver's Little Book of Hope [Kindle Edition]

(Natural News) A new study conducted by researchers at Harvard University showed that snoring while sleeping is correlated with the risk of contracting Alzheimer’s disease as it was found that people who are at-risk of the condition are more susceptible to it when they constantly experience difficulty in breathing while they’re asleep. Daytime sleepiness and sleep apnea are also signs that one might be suffering or might be vulnerable to risks of impaired attention, memory, and thinking, especially among people who are predisposed to cognitive decline, the research added.
“Individuals with SDB (sleep-disordered breathing) commonly report problems with cognition and may be at increased risk for dementia. Our results suggest that more severe overnight hypoxemia and sleepiness may be related to poorer cognitive function, especially attention, concentration, and process speed in middle-aged to older adults, and that the risk is greater among carriers of APOE, a known risk factor for Alzheimer’s disease,” study author Dr. Dayna Johnson said.
People who were at-risk of developing Alzheimer’s had in them a gene known as apolipoprotein ε4 (APOE-ε4) allele, which transports cholesterol and facilitates brain injury repair in healthy people. Around 20 percent of the people in the United States likely carry the APOE-ε4 allele, while 40 percent of Americans likely snore while sleeping, the study said.
“With use of this type of information, future risk stratification may help to identify individuals at increased risk for SDB-related cognitive effects,” Dr. Johnson said.

How the study was conducted

Around 1,752 people with an average of 68 participated in a sleep study. For each participant, the researchers calculated the:
  • Apnea-hypopnea index (AHI), which measures how many apnea or hypopnea episodes a person has per hour of sleep, and the
  • Percentage of time during sleep when their blood contained oxygen levels below 90 percent.
The researchers then tested the participants’ cognitive abilities via assessing these three areas:
  • Overall brain function, including attention and focus,
  • How fast the brain could grasp data and perform tasks (processing speed), and
  • Memory and attention using the Digit Span Test.
Aside from the Harvard Medical School in Boston, Massachusetts, the study was conducted by experts from the Wake Forest School of Medicine in Winston-Salem, North Carolina; the National Institute for Occupational Safety and Health; Stanford University School of Medicine; Brigham and Women’s Hospital; Beth Israel Medical Deaconness Center; University of Washington; and the U.S. Centers for Disease Control and Prevention.
The study analyzed data from the ongoing Multi-Ethnic Study of Atherosclerosis, which identified how various lifestyle factors impacted the risk of developing atherosclerosis. (Related: Alzheimer’s is really just ‘type-3’ diabetes, new research shows.)
The study, however, did not go on to further examine if the people who are predisposed to develop dementia because of sleep apnea and other sleep conditions really did get afflicted with Alzheimer’s in their old age. It also concluded that as far as factors go, having sleep apnea or other conditions has but a minimal effect to the chances of actually being susceptible to mental decline, England’s National Health Services said in a statement.

An unlikely ally against cognitive decline: strawberries

A study that was conducted earlier this month showed that strawberries could help deter the onset of age-related cognitive decline. Strawberries contained a compound called fisetin, which eases mental degradation in the mice that it were exposed to it. The mice that were not treated with this compound suffered from inflammation and cognitive difficulties, researchers said.

According to Pamela Maher, senior author and senior staff scientist at Salk’s Cellular Neurobiology Laboratory in La Jolla, California, “Mice are not people, of course. But there are enough similarities that we think fisetin warrants a closer look, not only for potentially treating Alzheimer’s disease but also for reducing some of the cognitive effects associated with aging, generally.”

Wednesday, November 24, 2010

How Beet Juice Prevents Dementia

Here is a great dementia resource for caregivers and healthcare professinals,

Here is information on being the best caregiver you can be

Here is a way for nurses administrators, social workers and other health care professionals to get an easyceu or two

Here are more interesting dementia brain boosting activities





Get your subscription to Activity Director Today's e magazine" />

Drinking beet juice can enhance blood blow to the brain in aging adults according to researchers doing a new study..This has been demonstated for the first time and could hold increased potential for fighting the progression of dementia.




"There have been several very high-profile studies showing that drinking beet juice can lower blood pressure, but we wanted to show that drinking beet juice also increases perfusion, or blood flow, to the brain," said Daniel Kim-Shapiro. "There are areas in the brain that become poorly perfused as you age, and that's believed to be associated with dementia and poor cognition."



The concentrations of nitrates found in beets is high.,High nitates are in celery, cabbage and other leafy green vegetables like some lettuce and spinach. When you eat high-nitrate foods, good bacteria in your mouth turn nitrate into nitrite. Researchers have discovered that nitrites can assist in opening up the blood vessels in your body. This increases ....Read all of How Beet Juice Prevents Dementia

Tuesday, January 12, 2010

Study finds snowballing effect in memory loss disease

Here is a great dementia resource for caregivers and healthcare professinals,

Here is information on being the best caregiver you can be

Here are more interesting dementia brain boosting Corrier-journal.comactivities

Here is a dementia music activity

LOS ANGELES,(Xinhua) -- Researchers have found a snowballing effect in the Alzheimer's disease and are proposing early preventive treatment for effectiveness.

The findings of the study, conducted by the New York University's Langone Medical Center, was published in the January issue of the Alzheimer's & Dementia journal.

The study, involving 213 adults with and without subjective cognitive impairment (SCI) over an average of seven years, found that 54 percent of the SCI adults had aggravated into mild cognitive impairment (MCI) and even full-blown dementia, or long-term memory loss.

The study also found that only 15 percent of the non-SCI adultshad developed MCI or dementia.

"The findings indicate that a significant percentage of people with early subjective symptoms may experience further cognitive decline, whereas few persons without these symptoms decline.

"If decline does occur in those without SCI symptoms, it takes considerably longer than for those with subjective cognitive symptoms," said Barry Reisberg, lead researcher at the Langone Medical Center.

"This is the first study to use mild cognitive impairment as well as dementia as an outcome criterion to demonstrate the outcome of SCI as a possible forerunner of eventual Alzheimer's disease," the lead researcher added.

Researchers can now hopefully work out potential preventive therapy of the eventual Alzheimer's disease, popularly known as the senile dementia, as "these intriguing results more fully describe the possible relationship between early signs of memory loss and development of more serious impairment."

Physicians can possibly better target the prevention of the SCI which starts more than 20 years before dementia becomes evident.

"This is critical to know, as we look for ways to define who is at risk and for whom the earliest interventions might be successful," said Neil Buckholtz from the National Institute on Aging which supports the research.

"These findings also underscore the importance of clinicians' asking about, and listening to, concerns regarding changes in cognition and memory among their aging patients."

The Alzheimer's is so far an incurable disease that advances from confusions, to mood swings, to language breakdowns, and to finally long-term memory loss
Blog Flux Directory
alzheimersideas - whereIstand.com

Fitness is important in dementia prevention. Click below for more info